SCHEMBL23201890

SCHEMBL23201890

Cc1nc(-c2ccc(OO)cc2)nc2c(Cl)cccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.40
NR4A2 P43354 5/20 0.39
MAPT P10636 4/20 0.39
PARP1 P09874 2/20 0.38
TNKS O95271 1/20 0.36
TNKS2 Q9H2K2 1/20 0.36
LMNA P02545 1/20 0.36
ADRA1A P35348 1/20 0.35
KCNH2 Q12809 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
DHFR P00374 1/20 0.35
RORC P51449 1/20 0.34
TP53 P04637 1/20 0.33
RXRA P19793 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
CYP2C19 P33261 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23040993 0.84 MAPT (0.39) DHODHMAPTALDH1A1CYP1A2HPGD
SCHEMBL23051055 0.84 DHODH (0.43) DHODHNR4A2MAPTPARP1TNKS
SCHEMBL29417337 0.84 DHODH (0.43) DHODHNR4A2MAPTPARP1TNKS
SCHEMBL23040824 0.84 NR4A2 (0.44) DHODHNR4A2PARP1TNKSTNKS2
SCHEMBL29417284 0.81 CYP1A1 (0.43) DHODHNR4A2PARP1TNKSTNKS2
SCHEMBL23040847 0.81 CYP1A1 (0.43) DHODHNR4A2PARP1TNKSTNKS2
SCHEMBL23040965 0.77 SMN1; SMN2 (0.41) DHODHMAPTLMNATP53ALDH1A1
SCHEMBL23040855 0.76 NR4A2 (0.40) DHODHNR4A2MAPTPARP1TNKS
SCHEMBL23040817 0.75 MRGPRX4 (0.57) TP53HPGDSMN1; SMN2
SCHEMBL29417307 0.75 MRGPRX4 (0.57) TP53HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021063856-A1 SUBSTITUTED 3,4-DIHYDROQUINAZOLINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2021-04-08 WO disclosed